Compare Domino's Pizza, Inc. (DPZ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs TransMedics Group Inc — how do they compare? Domino's Pizza, Inc. trades at $309.23 (market cap $10.21B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Domino's Pizza, Inc. is far larger — about 3.7× TransMedics Group Inc's market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and TransMedics Group Inc for 24 Days on average.
| DPZ | TMDX | |
|---|---|---|
Market Cap | $10.21B | $2.74B |
Volume | 916,737 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $150.42 |
52-Week Low | $282.89 | $61.99 |
Typical Hold Time | 106 Days | 24 Days |
Enterprise Value | $15.17B | $3.13B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $309.02, up 1.95% with a bullish technical signal despite recent earnings misses. The company maintains strong fundamentals with $4.94B revenue, 11.86% net margin, and positive cash flow trends. Recent news highlights dividend stability concerns amid high debt levels and store closures, while analyst consensus remains positive with a $373 price target representing 21% upside potential.
DPZ presents a value opportunity with reasonable valuation (P/E 17.5) but faces execution risks from consecutive earnings misses and substantial debt burden. The stock's 28% YTD decline creates potential for recovery if Q3 earnings beat expectations, though competitive pressures and franchisee challenges require monitoring for sustained growth.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
